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Background: Menstrual-linked asthma (MLA) is described in pre-menopausal women who
experience a deterioration of asthma control peri-menstrually. The clinical characteristics
of MLA remain incompletely defined. Our objective was to define the characteristics of MLA
in a large female asthma cohort.
Methods: Cross-sectional population survey. A comprehensive health questionnaire that
included questions about MLA was administered to 1260 consecutive female asthma patients
aged 12e55 years. Univariate and multivariate analyses were completed.
Results: The survey response rate was 43% (540/1260). The prevalence of self-reported MLA
was 11% (60/540). Univariate: women with MLA compared to women without MLA had more
urgent/emergent asthma-related healthcare visits/year, 6.18 (SDZ 6.67) vs. 4.71
(SDZ 5.91) (pZ 0.033), more emergency room visits, 1.50 (SDZ 3.57) vs. 0.88
(SDZ 2.27) (pZ 0.035), higher asthma-related absenteeism, 33/60 (57%) vs. 170/471
(37%) (pZ 0.003), and used almost twice the number of B2-agonist rescue doses/day, 1.13
(SDZ 1.70) vs. 0.68 (SDZ 1.32) (pZ 0.015). Multivariate: statistical significance was
retained for absenteeism (pZ 0.016) and B2-agonist use (pZ 0.007) but lost for urgent
healthcare visits (pZ 0.150) and emergency room visits (pZ 0.068).
Conclusions: Self-reported MLA is common. Women with MLA in our population had a greater
frequency of urgent healthcare visits, a higher rate of absenteeism, and used significantlyvolume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LTRA, leukotriene receptor
ist; MLA, menstrual-linked asthma; PEF, peak-expiratory flow; SD, standard deviation.
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Menstrual-linked asthma 1237more B2-agonist rescue than women without MLA. The association of increased health services
use was not confirmed on multivariate analysis indicating that baseline characteristics associ-
ated with MLA in our population affected this outcome. MLA should be considered by health-
care providers when developing an asthma management plan.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Menstrual-linked asthma (MLA) is a common clinical
phenomenon described in pre-menopausal women who
experience a deterioration of asthma control peri-
menstrually. MLA has published prevalence estimates
ranging between 11% and 40%.1e9 Identifying and charac-
terizing the MLA asthma phenotype is a fundamental step
toward understanding its pathobiology and toward facili-
tating the development of specific therapeutic strategies.
Physiologic changes occur during themenstrual cycle that
are related to asthma pathophysiology. Fluctuations in the
level of estrogen and progesterone are believed to affect
airway inflammation, bronchial responsiveness, and expira-
tory airflow. Specifically, it has been identified that inflam-
matory modulators important in the pathophysiology of
asthma including neutrophils, eosinophils, Th2-cytokines,
and leukotrienes, vary over the course of the menstrual
cycle.10e12 In addition, there is in vitroevidence of increased
B2-receptor responsiveness after exposure to progesterone,
and clinical evidence of increased peak-expiratory flow
(PEF) variability, bronchial responsiveness, symptoms, and
B2-agonist utilization in the late luteal and early follicular
phase of the menstrual cycle, when progesterone levels are
lowest.3,4,7,12e16 Within this evolving knowledge base there
is currently no unifying pathophysiologic model to explain
the relationship between hormonal fluctuation, inflamma-
tory mediators, and airway function in patients with MLA.
It is postulated that physiologic factors related to the
menstrual cycle contribute to increased asthma severity in
women with MLA. Compared to women who do not report
MLA, women with MLA have been shown to have a greater
frequency of bronchodilator utilization, a lower forced
expiratory volume in one second (FEV1) or PEF, require
a higher dose of inhaled corticosteroid to maintain asthma
control; and they also have a higher frequency of emer-
gency department visits, hospitalizations, and near-fatal
asthma episodes.2,3,7,8,12,16e19 However, there remain
many conflicting observations in the published literature.
While some investigators have reported that women with
MLA have higher degrees of atopy,20 are significantly older,7
and have had asthma longer,1,7 other studies report no
differences in these factors among patients.2,4,20
Although there is currently very limited information on
MLA specific therapeutic strategies, studies suggest that
a more complete understanding of MLA pathophysiology
may lead to specific targeted therapeutic interventions. For
example, subjects reporting MLA with decreased PEF rates,
and high levels of leukotriene C4 premenstrually, demon-
strated improvements in PEF and symptom scores after
treatment with leukotriene receptor antagonists.12 In
addition, subjects with MLA placed on oral contraceptive
pills (which suppress the luteal phase of the menstrualcycle) demonstrated attenuation of cyclical changes in PEF
and adenosine monophosphate bronchial responsiveness.16
In another study, salmeterol was an effective method to
reduce short-acting B2-agonist utilization and to eliminate
a premenstrual fall in PEF in women with MLA.21
In this study, we sought to identify and to define the
clinical characteristics of the MLA phenotype in a large
outpatient clinic population from primary and specialty
care practices. Current descriptions of MLA are limited by
observations derived predominantly from small studies,
which are influenced by ascertainment bias. A more accu-
rate definition of the MLA asthma phenotype will inform
future investigation into pathophysiologic mechanisms and
specific therapeutic strategies.
Methods
Study design
Within a cross-sectional design we administered a compre-
hensive health questionnaire to 1260 consecutive subjects
attending two primary care community asthma projects
and a specialty care asthma centre, between July 2004 and
August 2008 in Ontario, Canada. The questionnaire was an
integrated component of the patients’ clinical evaluation
and included demographic information, an asthma-specific
history, medication use, symptom profile over the previous
4 weeks, healthcare utilization and absenteeism in the
prior year, and co-morbid medical conditions. All regional
asthma clinics utilizing this clinical questionnaire tool
participated in the study.
Subjects aged 12e55 years self-identifiedwith orwithout
MLA by answering the question, “Does your asthma change
during your menstruation?” If the response was affirmative,
the subjectwas asked to qualify thechange, asworse, better,
or uncertain. Subjects answering that their asthma changed
and that it worsened were designated as self-reported MLA.
Spirometric measurements were recorded for all subjects
after the questionnairewas administered. Normal spirometry
values are as described by Morris.22 Symptom control
benchmarks were recorded as defined by the Canadian
AsthmaConsensusGuidelines.23e25 Urgent visitswere defined
as unscheduled healthcare encounters for asthma symptoms
including: Family physician; walk-in clinic, or emergency
department visits, and hospital admission. Absenteeism was
defined as a day missed at school or work because of asthma.
Patient population
Women with a clinical diagnosis of asthma from primary and
specialty care were included in the study. We excluded
women aged <12 and >55 years of age.
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Subjects with MLA were compared to those without MLA
using chi-square tests for comparing proportions and
unpaired t-tests for comparing continuous variables. The
number of healthcare visits, number of medications, and
doses of rescue medication were compared using a Wil-
coxon two-sample test (non-parametric). To compare
disease associations for conditions with a low frequency we
used the Fisher’s exact two-tailed test. Baseline charac-
teristics found to be statistically significant at the 0.10 level
were considered for covariate adjustment using logistic
regression for proportions (i.e. symptom benchmarks),
analysis of covariance for continuous variables (i.e. FEV1),
and negative binomial regression for count data (i.e.
number of urgent healthcare visits).
Ethics
The study protocol was approved by the “Office of Research
Ethics” at the University of Western Ontario (REB# 15913E).
The data were collected prospectively using a question-
naire tool that was a component of the patients’ clinical
care, therefore a waiver of consent was granted for this
analysis.
Results
Data from all individual questionnaires were reviewed for
completeness and 548 complete records were identified on
our primary review e 224 from primary care asthma clinics
and 324 from a specialty care asthma centre. Upon
secondary review, a further 8 records were excluded
because of incomplete data, leaving 540 records for
a response rate of 43% (540/1260). Subjects completing the
questionnaire compared to non-participants were younger
with a mean age of 34.1 (SDZ12.2) vs. 38.4 (SDZ12.2)
(p< 0.001) and more likely to be non-smokers with a non-
smoking prevalence of 67.8% vs. 61.2% (pZ 0.022).
Sixty-nine (69) subjects reported that their asthma
changed during the menstrual cycle; 2/69 (3%) reported
that their asthma improved and 7/69 (10%) were uncertain
about how their asthma changed. These 9 subjects could
not be classified as MLA or non-MLA and were excluded.
Sixty (60) subjects reported that their asthma changed and
that it became ‘worse’, meeting our defined criteria for
self-reported MLA. The prevalence of MLA in our population
was therefore 60/540 (11%).
Subject data were stratified by the source as primary or
specialty care. As the comparative results did not differ,
the combined results are presented.
General characteristics
Women who reported MLA were similar to women without
MLA when comparing multiple general characteristics
including age, age at diagnosis, duration of asthma, and
smoking status (Table 1). In contrast, women with MLA were
significantly more likely to report a family history of hayf-
ever, 32/60 (71%) vs. 211/471 (51%), (pZ 0.010) or a familyhistory of allergies or eczema, 47/60 (94%) vs. 304/471
(70%) (p< 0.001) and 23/60 (51%) vs. 149/471 (35%),
respectively, and were more likely to report asthma wors-
ening during pregnancy, 13/24 (54%) vs. 39/129 (30%)
(pZ 0.023) than women without MLA (Table 1).
Asthma medication
Prescribed asthma control medications were similar in both
groups (Table 1). We did not identify that subjects with MLA
were prescribed more asthma control medications. Of note,
the majority of subjects in both groups were on anti-
inflammatory therapy and almost half were on inhaled
corticosteroid (ICS)/long-acting B2-agonist (LABA) combi-
nation therapy. Subjects with MLA used asthma rescue
medications more frequently and had a higher total
reported dose of B2-agonist than non-MLA subjects.
Specifically, a higher proportion of MLA subjects used
rescue medication doses 4 times/week, 29/60 (55%) vs.
159/471 (37%) (pZ 0.010), and more doses per day, 1.13
(SDZ1.70) vs. 0.68 (SDZ1.32) (pZ 0.015) (Table 2).
Statistical significance was maintained in a multivariate
model (Table 2: adjusted p-values).
Asthma symptoms
These data are presented as individual symptoms and as
a composite of 2 symptoms outside of the Canadian
Asthma Consensus Guidelines benchmark criteria for
acceptable control.23e25 The symptom profile describes
symptoms during the 4 weeks prior to the subject’s initial
clinical visit. Composite and individual symptom measures
were similar between the two groups (Table 2).
Absenteeism
Women with MLA were much more likely to miss school or
work because of asthma than women without MLA, 33/60
(57%) vs. 170/471 (37%) (pZ 0.003) (Table 2). Subjects in
the MLA group had an almost 3-fold higher mean number of
days absent vs. the non-MLA group, 13.6 vs. 4.2 days
(pZ 0.043). Statistical significance was maintained in
a multivariate model (Table 2: adjusted p-values).
Lung function
The FEV1, forced vital capacity (FVC), and FEV1/FVC ratio
were not different in the MLA and non-MLA groups (Table 2).
Healthcare utilization
Women with MLA had more urgent/emergent asthma-
related healthcare visits in the past 12 months, 6.18
(SDZ6.67) vs. 4.71(SDZ5.91) (pZ 0.033), including
more emergency room visits, 1.50 (SDZ3.57) vs. 0.88
(SDZ2.27) (pZ 0.035), than women without MLA.
Although women with MLA were more likely to have ever
been admitted to the intensive care unit for asthma, 5/60
(10%) vs. 18/471 (4%), this difference is not significant
(pZ 0.163). The statistical significance identified in the
Table 1 Patient characteristics.
Characteristic Women without MLA (nZ 471) Women with MLA (nZ 60) p Value
Age
Mean age (SD) 33.8 (12.4) 36.6 (10.3) 0.097
Mean age at diagnosis 18.8 (13.0) 19.0 (10.3) 0.934
Age at diagnosis categories 0.318
Age 12 109 (36.5%) 9 (25.0%)
Age 13 to 19 59 (19.7%) 10 (27.8%)
Age >19 131 (43.8%) 17 (47.2%)
Duration of asthma (SD) 14.7 (10.6) 15.7 (10.3) 0.594
General characteristics
BMI 28.3 (7.6) 29.6 (9.0) 0.210
Caucasian 420 (96.1%) 52 (98.1%) 0.464
Smoking status 0.401
Former 74 (15.9%) 13 (22.0%)
Current 75 (16.1%) 7 (11.9%)
Family history of asthma 248 (57.8%) 33 (63.5%) 0.435
Asthma worsening during pregnancy 39/129 (30.2%) 13/24 (54.2%) 0.023
Allergy
Personal history of allergy 320 (69.4%) 44 (78.6%) 0.156
Family history
Hayfever 211 (51.0%) 32 (71.1%) 0.010
Eczema 149 (35.4%) 23 (51.1%) 0.038
Allergies 304 (70.4%) 47 (94.0%) <0.001
Asthma control medication
Any controller 368 (78.1%) 46 (76.7%) 0.797
ICS only 129 (27.4%) 20 (33.3%) 0.334
ICSþ LABA 235 (49.9%) 28 (46.7%) 0.638
LTRA only 83 (17.6%) 15 (25.0%) 0.165
Total number 1.00 (0.70) 1.17 (0.87) 0.170
Data presented as mean (SD) and as frequency (%) as appropriate. SDZ standard deviation; ICSZ inhaled corticosteroid;
LTRAZ leukotriene receptor antagonist; LABAZ long acting B2-agonist; BMIZ body mass index; and MLAZmenstrual-linked asthma.
Menstrual-linked asthma 1239univariate model is lost in a multivariate model (Table 2:
adjusted p-values).
Disease associations
Women with MLA were almost twice as likely to report
having eczema, 21/60 (36%) vs. 87/471 (19%) (pZ 0.002),
three times as likely to report heart disease, 6/60 (10%) vs.
15/471 (3%) (pZ 0.021), and more than twice as likely to
report rheumatoid arthritis, 7/60 (12%) vs. 22/471 (5%)
(pZ 0.033) (Table 3).
Discussion
In a large cohort of pre-menopausal asthmatic women who
received care in primary and specialty care asthma clinics,
we identified that 11% have self-reported menstrual-linked
asthma. MLA in our population was characterized by
a significantly greater frequency of urgent healthcare
visits, a higher rate of absenteeism, and a more than 2-fold
increase in the frequency of near-fatal asthma episodes;
although the latter comparison did not reach statistical
significance. We also found that women with MLA havesignificantly higher B2-agonist utilization and we identified
an association with other inflammatory conditions including
heart disease, rheumatoid arthritis, and eczema (Table 3).
To our knowledge, our study is the largest to date to
examine the clinical characteristics of women with
menstrual-linked asthma, the only study to explore disease
associations, and only the second study to use multivariate
analysis to adjust for potentially confounding patient
characteristics.2
While it is clinically concerning to identify a statistically
significant increase in total urgent/emergent visits, an
increase in emergency room visits, and a near statistically
significant increase in hospitalizations and near-fatal
asthma episodes on univariate analysis; in a multivariate
model these increases lose statistical significance. This
suggests that this difference is not related to the MLA
phenotype, or that other factors account for a portion of
the identified difference, or that the association is real but
our data lacks the precision required to reach a statistically
significant conclusion. Although consistent with the repor-
ted literature the univariate associations identified in our
study must be interpreted cautiously.1,2,8,17 Eliasson and
colleagues published the only study to date that reports
increased hospitalization based on a multivariate analysis.2
Table 2 Symptoms, spirometry, absenteeism, and health services utilization.
Characteristic Women without
MLA (nZ 471)
Women with
MLA (nZ 60)
p Value Adjusted
p value
Symptoms
2 Parameters> benchmark 107 (23.1%) 12 (20.7%) 0.679 0.429
Cough 4 weekly 235 (51.8%) 24 (43.6%) 0.255 0.229
Wheeze 4 weekly 127 (28.4%) 16 (29.6%) 0.852 0.815
Dyspnea 4 weekly 154 (33.9%) 17 (29.8%) 0.537 0.389
Chest tightness 4 weekly 126 (28.2%) 21 (38.9%) 0.103 0.340
Nocturnal symptoms 1 weekly 116 (26.3%) 18 (33.3%) 0.273 0.481
Rescue/relief medication
Doses 4 weekly 159 (36.5%) 29 (54.7%) 0.010 0.007
Average use (doses/day) 0.68 (1.32) 1.13 (1.70) 0.015 0.012
Asthma-related absenteeism
Absent from school or work past year 170 (36.9%) 33 (56.9%) 0.003 0.016
Mean days absent 4.2 (12.6) 13.6 (52.9) 0.043 0.010
Spirometry
FEV1 (Litres) 2.82 (0.67) 2.69 (0.70) 0.189 0.457
FEV1 % predicted 94.3 (24.8) 93.5 (20.8) 0.590 0.971
FVC (Litres) 3.56 (0.66) 3.46 (0.69) 0.378 0.680
FEV1/FVC % ratio 78.7 (11.4) 77.2 (10.6) 0.182 0.373
Asthma-related health service use e visits in the prior year
Total # of urgent/emergent care visits 4.71 (5.91) 6.18 (6.67) 0.033 0.150
Hospital admissions 0.09 (0.50) 0.23 (0.87) 0.065 0.083
Unscheduled family MD visits 2.63 (3.64) 3.02 (3.22) 0.181 0.442
Walk-in clinic visits 1.12 (2.22) 1.43 (2.51) 0.601 0.653
Emergency room visits 0.88 (2.27) 1.50 (3.57) 0.035 0.068
Data presented as mean (SD) and as frequency (%). SDZ standard deviation; FEV1Z forced expiratory volume in 1 s; and FVCZ forced
vital capacity. Calculation of mean days absent includes those with no absences; MLAZmenstrual-linked asthma. Adjusted p value
derived from the multivariate analysis.
Table 3 Disease associations.
Medical condition Women without MLA (nZ 471) Women with MLA (nZ 60) p Value
Anaphylaxis 44 (9.5%) 6 (10.3%) 0.846
ASA reactions 11 (2.4%) 1 (1.7%) >0.999a
Cancer 7 (1.5%) 1 (1.7%) >0.999a
Diabetes 23 (5.0%) 7 (12.1%) 0.065a
Eczema 87 (18.9%) 21 (36.2%) 0.002
Gastrointestinal bleeding 9 (2.0%) 2 (3.5%) 0.353a
Heartburn (GERD) 133 (28.9%) 23 (39.7%) 0.091
Heart disease 15 (3.3%) 6 (10.3%) 0.021a
High blood pressure 51 (11.1%) 5 (8.6%) 0.572
Hives 152 (33.0%) 15 (25.9%) 0.275
Inflammatory bowel disease 24 (5.2%) 6 (10.3%) 0.130a
Kidney disease 8 (1.7%) 1 (1.7%) >0.999a
Liver disease 6 (1.3%) 2 (3.5%) 0.222a
Nasal polyps 21 (4.6%) 2 (3.5%) >0.999a
Other lung disease 25 (5.4%) 4 (6.9%) 0.552a
Peptic ulcer disease 11 (2.4%) 3 (5.2%) 0.198a
Rheumatoid arthritis 22 (4.8%) 7 (12.1%) 0.033a
Rhinosinusitis 163 (35.4%) 19 (32.8%) 0.696
None apply 101 (21.9%) 8 (13.8%) 0.153
a Statistical comparisons made using Fisher’s exact two-tailed test. All other comparisons made using chi-square tests for comparing
proportions.
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Menstrual-linked asthma 1241There are surprisingly few contemporary studies that
have evaluated MLA in a clinical setting.1e4,7,8,12,18,21 (Table
4). Until this study, the largest evaluation was published by
Suzuki and colleagues, who used univariate analysis to
examine 480 women in Japan. They identified a prevalence
of 11% in their population.8 Also similar to our study, Suzuki
determined that women with MLA had more severe asthma,
a higher frequency of exacerbation, and increased health
services use compared to women without MLA. Distinct
from our study their MLA cohort had more smokers and had
a higher utilization of asthma control medications.8
Our finding that women with MLA used B2-agonists more
frequently, and at higher doses, contrasts sharply with our
finding that other measures of current asthma control were
not different. Despite the similarity of baseline symptoms
and FEV1, a higher proportion of women with MLA usedTable 4 Research in context e identification and evaluation of
Study Total
subjects
Subjects
with MLA
Prevalence
(%)
Self-reporta Sel
to
Agarwal
(1997)1
100 23 23 Y Y
Eliasson
(1986)2
57 19 33 Y N
Nakasato
(1999)12
45 5 11 Yb Y
Gibbs
(1984)3
91 36 40 Y Y
Hanley
(1981)4
102 36 36 Y Y
Shames
(1988)7
32 9 28 Y Y
Magadle
(2001)21
67 13 19 N N
Suzuki
(2007)8
480 56 11 Y N
Current
study 2012
540 60 11 Y N
a MLA defined by self-report means questionnaire and/or patient sy
b MLA diagnosis required peak flow changes in addition to self-report
strategies published after 1970, that identify and characterize MLA, amore than three B2-agonist doses per week; and this cohort
used almost twice the mean daily dose of B2-agonist
compared to women without MLA. This observation aligns
with the hypothesis that a hormonally mediated reduction
in B2-receptor responsiveness is important in the patho-
physiology of MLA13 and may contribute to our under-
standing of disease severity in MLA. In MLA it has been
demonstrated that the bronchoconstrictor effects of ozone
are greater during the early follicular phase of menstrua-
tion, when progesterone levels are lowest.14 Furthermore,
regular B2-agonist utilization has been independently
associated with a loss of bronchoprotection and with an
increased risk of fatal and near-fatal asthma exacer-
bations.26e28 Although speculative, it is interesting to
consider that physiologic changes during the menstrual
cycle could contribute directly to disease severity: viawomen with MLA in clinical practice.
f-report related
physiology
Comparative findings MLA vs. non-MLA
MLA had longer duration of asthma,
were more symptomatic, increased
frequency of emergency visits and
hospitalizations. Peak flow values fell
peri-menstrually in MLA but not in
non-MLA (nZ 10).
Pulmonary symptom scores worsened
peri-menstrually in MLA vs. non-MLA.
Higher frequency of hospitalization in MLA.
Leukotrienes were increased in MLA
and MLA was attenuated by a leukotriene
receptor antagonist.
21/36 women with MLA compared to
12 controls. A peri-menstrual fall in
peak flow was identified in MLA but
not in controls.
Peak flow rate was reduced
peri-menstrually in subjects who
reported MLA and not in subjects
without MLA.
Subjects with MLA were older with a
longer duration of asthma, and had
peri-menstrual differences in B2-agonist
use and peak flow.
MLA defined by peak flow and B2-agonist
use. Salmeterol prevented MLA related
changes in 54% of subjects.
MLA cohort had more severe disease,
increased medication use including
more oral corticosteroid, and had
more ‘asthma attacks’.
MLA cohort characterized by a higher
frequency of urgent health services
utilization, absenteeism, higher
frequency and dose of B2-agonist,
and a higher prevalence of heart
disease, rheumatoid arthritis, and eczema.
mptom dairy.
. Inclusion criteria: clinical studies identified by electronic search
nd >10 subjects with known asthma. YZ yes and NZ no.
1242 J. Thornton et al.hormonally mediated changes in B2-receptor responsive-
ness, or symptom perception, or via changes in broncho-
protection; and indirectly because of the increase in B2-
agonist utilization that these physiologic changes lead to.
Despite its strengths, this study has some limitations. A
lower than expected response rate to our comprehensive
questionnaire may have been secondary to subject fatigue
as the questionnaire was lengthy. Given our response rate
we cannot exclude that selection bias influenced our
results. We compared the characteristics of participants to
non-participants and found that participants were younger
and were more likely to be non-smokers than non-
participants. Additionally, it is possible that subjects with
more severe menses-related symptoms responded dispro-
portionately and are over-represented in our cohort
increasing the reported prevalence. We noted, however,
that our reported prevalence is consistent with that of
Suzuki and colleagues.8 In our analysis of disease associa-
tions we did not adjust for multiple comparisons, therefore
the described associations must be considered exploratory.
Despite its reported prevalence and decades after the
first description of MLA it remains the least well character-
ized of the trigger-related asthma phenotypes.29 It was not
methodologically possible in this study therefore, to utilize
a validated case definition for MLA, as no such case definition
exists. To minimize the potential effects of ascertainment
bias, which has heavily influenced contemporary MLA liter-
ature (Table 4), a significant objective of this study was to
evaluate the clinical characteristics of MLA in a large female
asthma cohort. Self-report was an efficient method to
complete the study in a cohort of this size. More importantly
a majority of published clinical studies have used self-report
as amethod for identifying womenwith MLA, and a review of
that literature suggests that it is a valid method to define
MLA. In Table 4 we identified five studies that measured
physiologic parameters in self-identified MLA cohorts con-
firming non-parallel changes in premenstrual PEF that
discriminated MLA from non-MLA.1,3,4,7,12 Despite these
reassuring findings, we cannot exclude the possibility that
we misclassified some subjects by utilizing self-reported
MLA as our case definition.
We also used patient self-report to collect outcome
measures including B2-agonist utilization and urgent health
services utilization. Although self-reported health services
utilization is common in the chronic disease management
literature, and although self-report has been validated
against administrative databases in other settings, utiliza-
tion in this study was not validated against an administra-
tive dataset.30e32 We did, however, utilize methods to
increase the accuracy of the self-reported data including
measuring acute events that are easily understood by the
subject (exacerbations requiring urgent care), and utilizing
the shortest meaningful reporting interval (4 weeks) for B2-
agonist use.33
Defining the clinical characteristics of women with MLA
is required to build upon our understanding of this entity
and is a requisite first step toward the development of an
accurate phenotypic description or validated case defini-
tion. We define the clinical characteristics of MLA in a large
cohort of women from primary and specialty care practices.
Women with MLA should be identified as a component of
health risk stratification and MLA should be considered byhealthcare providers when developing an individualized
asthma management plan. We identify the following
research needs: formal validation of a case definition for
MLA that includes clinical, physiologic, and psychophysical
measures; and to explore the hormonal influences on B2-
receptor responsiveness and symptom perception
throughout the menstrual cycle.
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